WinstonWınston
Back
MedX Health logo

MedX Health

MDXHF
Medical - Devices · Healthcare
Price
$0.03
+0.00 (+0.00%)
Market Cap
$8.2M
Exchange
Other OTC
Winston Score
Winston looking sleepy
No score yet — Winston is napping.
We couldn’t gather enough financial data to score this stock reliably.

Share count rising — dilution

+64.5% over 4y

The company has issued more shares over this period, which dilutes each existing shareholder’s stake.

Diluted shares outstanding: 180.2M (2021) → 296.4M (2025)

Winston Score History

The full picture

MedX Health Corp is a small Canadian healthcare technology company that makes devices and software for examining skin. Its main product is a handheld device called SIAscopy, which uses light to scan moles and skin lesions and help doctors decide if something might be skin cancer. The main customers are doctors, dermatologists, and clinics looking for tools to catch skin problems early.

The company earns money by selling its scanning devices and through service or software fees tied to those devices. MedX operates primarily in Canada and is working to expand into other markets, including the United States and Europe. It is a very small company with a negative gross margin, meaning it currently costs more to deliver its products than it earns from them, which is a significant financial risk. The key challenge ahead is reaching enough scale to cover its costs, as the company depends heavily on growing its customer base to become financially sustainable.

Growth Profile

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

+60.4% YoY

YoY Growth Rate

Revenue accelerating

EPS Growth

+35.6% YoY

YoY Growth Rate

EPS growth accelerating

R&D Spend

C$499,591/ year

Declining (-5% vs prior year)

105.6% of revenue

5.9x the sector average (18%)

R&D spend declining — could signal cost-cutting or efficiency

Insider Activity

34.6%ownership

Flat

Insider ownership roughly steady over the past year

Cash Runway

~0 months

C$36,548 cash & investments

Short runway — potential dilution ahead through share issuance

Revenue accelerating

MedX Health grew revenue 60% year-over-year and the growth rate is speeding up. That's the kind of momentum growth investors look for — the question is whether margins can follow.

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Profit per sale
Gross Margin
29.0%
Modest — 29.0% gross margin
Profit after running costs
Operating Margin
-514.8%
Losing money on operations — -514.8%
Return on the money invested
ROCE
N/A
Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales growth
Sales YoY
+9.4%
Steady sales growth (+9.4% YoY)
Profit growth
EPS YoY
N/A
Data not available
How steady the profit is
EPS Consistency
3/8 quarters
Earnings rarely grow — volatile business

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Profit that turns into cash
Cash Conversion
N/A
Data not available
Spare cash per sale
FCF Margin
-747.8%
Burning cash (-747.8%)

Free cash flow is negative. They are burning cash, not generating it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

What it owes vs what it owns
Debt / Equity
N/A
Data not available
Covers its interest
Interest Cover
N/A
Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

Price vs profit
P/E Ratio (TTM)
N/M
Negative earnings — P/E not meaningful
Cheaper or dearer next year
P/E vs Forward
N/A
not available
Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Not applicable for this business.
🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.
Start free trial